Ascend Pharma

Ascendis Pharma is a biopharmaceutical company headquartered in Denmark, dedicated to improving patients' lives through its innovative TransCon (Transient Conjugation) technology platform. The TransCon platform allows for the development of long-acting prodrugs that release therapeutic proteins, peptides, or small molecules in their active, unmodified form at a controlled rate. The company's lead product, Skytrofa (lonapegsomatropin), is FDA-approved for pediatric growth hormone deficiency, marking a significant milestone in its endocrinology portfolio. Ascendis is also advancing late-stage programs for hypoparathyroidism and achondroplasia, alongside an emerging pipeline in oncology. By leveraging its platform to optimize the pharmacokinetics and pharmacodynamics of established drug classes, Ascendis aims to create best-in-class therapies with improved efficacy, safety, and convenience.